To determine whether the acute metabolic changes observed with SGLT2 inhibition were sustained and associated with enhanced cardiac function in the failing heart during more chronic dapagliflozin treatment, we next performed echocardiography and metabolic analyses in a separate cohort of heart-failure rats after 3 weeks of dapagliflozin treatment (~1 mg/kg body weight/day in drinking water) (Figures 7 and 8). The gene discussed is SLC5A2; the disease is heart failure.